Please login to the form below

Not currently logged in


This page shows the latest ophthalmology news and features for those working in and with pharma, biotech and healthcare.

Novartis negotiates ex-US rights to Spark gene therapy

Novartis negotiates ex-US rights to Spark gene therapy

Novartis is an established global player in ophthalmology with its Alcon division and this could help Luxturna’s roll-out in the EU if approved by the EMA. ... This collaboration builds on our commitment to ophthalmology, ”commented Shreeram Aradhye,

Latest news

More from news
Approximately 7 fully matching, plus 96 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Collaboration, licence. 830. Molecular Partners/ Allergan. Option exercise for 2 DARPins from Allergan's ophthalmology alliance signed in 2012.

  • The good, the bad and the ugly The good, the bad and the ugly

    Ophthalmology. Ophthalmology is dominated by a small number of the same therapies marketed by different companies in different regions; Regeneron, Bayer and Santen all market Eylea, whereas Novartis and Roche market ... Biogen was the largest seller in

  • Deal Watch - May 2017 Deal Watch - May 2017

    The acquisition of Akorn, a US based company that manufactures “alternate”formulations such as liquids, gels and injectables  and markets a range of products with a focus on ophthalmology will cost

  • A rare talent A rare talent

    in two February deals, and then in August picking up Foresight Biotherapeutics, an ophthalmology company for $300m.

  • A rising tide A rising tide

    business unit head in its immunology and ophthalmology sectors.

More from intelligence
Approximately 3 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 18 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...